Sage Therapeutics (SAGE)

Add to Watchlists
Create an Alert
156.16 -5.08  -3.15% NASDAQ Jun 22, 15:02 Delayed 2m USD

Sage Therapeutics Income Statement (Quarterly)

Export Data

March 2018 - December 2015

Previous Periods

Income (Quarterly) 2018-03 2017-12 2017-09 2017-06 2017-03 2016-12 2016-09 2016-06 2016-03 2015-12
Sales and Marketing Expense Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
General and Administrative Expense Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
SG&A Expense 26.12M 17.62M 14.50M 13.53M 10.93M 12.53M 7.818M 7.697M 7.133M 7.399M
Research and Development Expense 49.27M 50.89M 58.29M 55.90M 45.20M 42.00M 29.07M 26.10M 23.58M 20.38M
Net Operating Interest Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Other Operating Expenses Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Total Operating Expenses Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Operating Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Net Non-Operating Interest Income Expense Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Other Income and Expenses Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Net Interest Income 3.529M 1.043M 0.6770M 0.6720M 0.7070M 0.4940M 0.2750M 0.2660M 0.1750M 0.0630M
Pre-Tax Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Income from Continuing Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Preferred Stock Dividend Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Net Income -74.60M -69.42M -73.72M -70.20M -56.78M -55.90M -37.80M -34.75M -30.54M -28.56M
Normalized Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EBITDA Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Reconciled Depreciation Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EBIT Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Basic EPS (Quarterly) 2018-03 2017-12 2017-09 2017-06 2017-03 2016-12 2016-09 2016-06 2016-03 2015-12
EPS Basic from Continuing Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Normalized Basic EPS Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Basic Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Diluted EPS (Quarterly) 2018-03 2017-12 2017-09 2017-06 2017-03 2016-12 2016-09 2016-06 2016-03 2015-12
EPS Diluted from Continuing Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Normalized Diluted EPS Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Diluted -1.680 -1.720 -1.970 -1.880 -1.520 -1.550 -1.150 -1.080 -0.9700 -1.000
Shares Data (Quarterly) 2018-03 2017-12 2017-09 2017-06 2017-03 2016-12 2016-09 2016-06 2016-03 2015-12
Average Basic Shares Outstanding Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Average Diluted Shares Outstanding Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
SEC Filing Links 2018-03 2017-12 2017-09 2017-06 2017-03 2016-12 2016-09 2016-06 2016-03 2015-12
As Originally Reported AOR AOR AOR AOR AOR AOR AOR AOR AOR AOR
Restated Restated Restated Restated Restated Restated Restated

March 2018 - December 2015

Previous Periods

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.